Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future

This article was originally published in The Pink Sheet Daily

Executive Summary

A lack of good clinical trial data on the use of Sprycel, high-dose Glivec and Tasigna in imatinib-resistant chronic myeloid leukemia patients leads to rejection by NICE in a draft guidance.
Advertisement

Related Content

Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap
Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap
Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
NICE Likely To Lose Cost-Watchdog Status By 2013
U.K. Provides £50 Million Extra For Cancer Drugs
UK's NICE Says No To Two CML Drugs; Invites Cost-Sharing Schemes
UK's NICE Says No To Two CML Drugs; Invites Cost-Sharing Schemes

Topics

Advertisement
UsernamePublicRestriction

Register

PS072334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel